Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Ultragenyx Pharmaceutical ( (RARE) ).
On March 30, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for UX016, an investigational small molecule prodrug of sialic acid being developed as a substrate replacement therapy for GNE myopathy, a rare, severely debilitating inherited neuromuscular disorder. Externally funded by a patient group through clinical proof-of-concept, UX016 is designed with a hydrophobic fatty acid tail to improve delivery and uptake of sialic acid in muscle, and a first-in-human Phase 1/2 trial in approximately 24 adults with GNE myopathy in the United States is expected to start in the second half of 2026, assessing safety, pharmacokinetics, muscle delivery, and functional outcomes over up to 48 weeks of treatment.
The most recent analyst rating on (RARE) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.
Spark’s Take on RARE Stock
According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and sharply reduced equity—alongside a technically weak price trend. These are partially offset by constructive earnings-call guidance and cost-reduction plans targeting profitability in 2027, plus continued revenue growth, but regulatory and execution risks remain material.
To see Spark’s full report on RARE stock, click here.
More about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases. The company’s pipeline includes investigational treatments targeting serious inherited disorders with high unmet medical need, positioning it within the niche rare-disease segment of the pharmaceutical industry.
Average Trading Volume: 2,453,904
Technical Sentiment Signal: Sell
Current Market Cap: $1.87B
For an in-depth examination of RARE stock, go to TipRanks’ Overview page.